Treating hepatitis C: Can you teach old dogs new tricks?

Hepatology

Volumn 42, Issue 6, 2005, Pages 1455-1458

  Rice, Charles M ^a   You, Shihyun ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CYCLOPHILIN; CYCLOPHILIN B; CYCLOSPORIN A; INOSINATE DEHYDROGENASE INHIBITOR; INTERFERON; MUTAGENIC AGENT; NUCLEOSIDE ANALOG; RIBAVIRIN; RNA POLYMERASE; TACROLIMUS; CYCLOSPORIN; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; PEPTIDYLPROLYL ISOMERASE; VIRUS PROTEIN; VIRUS RNA;

BINDING AFFINITY; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; LIVER CELL CULTURE; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; RNA INTERFERENCE; VIRUS REPLICATION; ARTICLE; BIOSYNTHESIS; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ANTIVIRAL AGENTS; CYCLOPHILINS; CYCLOSPORINE; HEPACIVIRUS; HEPATITIS C; HUMANS; PEPTIDYLPROLYL ISOMERASE; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 32944481736     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20975     Document Type: Note

References (29)

1. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. HEPATOLOGY 1997;26:83S-88S.
2. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-1578.
3. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999;19(Suppl 1):57-65.
4. Hong Z. The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact? HEPATOLOGY 2003;38:807-810.
5. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-972.
6. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. HEPATOLOGY 2002;35:1002-1009.
7. Sherlock S, Thomas HC. Treatment of chronic hepatitis due to hepatitis B virus. Lancet 1985;2:1343-1346.
8. De Clercq E. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv Virus Res 1993;42:1-55.
9. Snell NJ. Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2001;2:1317-1324.
10. Busuttil RW, Lake JR. Role of tacrolimus in the evolution of liver transplantation. Transplantation 2004;77:S44-S51.
11. Fanghanel J, Fischer G. Insights into the catalytic mechanism of peptidyl prolyl cis/trans isomerases. Front Biosci 2004;9:3453-3478.
12. Heitman J, Cullen BR. Cyclophilin B escorts the hepatitis C virus RNA polymerase: a viral achilles heel? Mol Cell 2005;19:145-146.
13. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19:111-122.
14. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. HEPATOLOGY 2003;38:1282-1288.
15. Miyanari Y, Hijikata M, Yamaji M, Hosaka M, Takahashi H, Shimotohno K. Hepatitis C virus non-structural proteins in the probable membranous compartment function in viral genome replication. J Biol Chem 2003;278:50301-50308.
16. Ikeda M, Sugiyama K, Mizutani T, Tanaka T, Tanaka K, Sekihara H, et al. Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. Virus Res 1998;56:157-167.
17. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004;313:42-47.
18. Braaten D, Luban J. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J 2001;20:1300-1309.
19. Randall G. Progress toward the therapy of hepatitis with RNAi. HEPATOLOGY 2005;41:1220-1222.
20. Jackson AL, Linsley PS. Noise amidst the silence: off-target effects of siRNAs? Trends Genet 2004;20:521-524.
21. Sledz CA, Williams BR. RNA interference and double-stranded-RNA-activated pathways. Biochem Soc Trans 2004;32:952-956.
22. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 2005;129:1031-1041.
23. Schmidt-Mende J, Bieck E, Hugle T, Penin F, Rice CM, Blum HE, et al. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 2001;276:44052-44063.
24. Price ER, Jin M, Lim D, Pati S, Walsh CT, McKeon FD. Cyclophilin B trafficking through the secretory pathway is altered by binding of cyclosporin A. Proc Natl Acad Sci U S A 1994;91:3931-3935.
25. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004;63:71-180.
26. Brown RS Jr. Hepatitis C and liver transplantation. Nature 2005;436:973-978.
27. Cotler SJ, Morrissey MJ, Wiley TE, Layden TJ, Jensen DM. A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. J Clin Gastroenterol 2003;36:352-355.
28. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003;38:567-572.
29. Inoue K, Yoshiba M. Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease. Transplant Proc 2005;37:1233-1234.